drugset / Trial / NCT06068543

Reducing Frailty for Older Cancer Survivors Using Supplements II

NCT06068543

Phase 2 Suspended 118 enrolled University of Rochester
RandomizedParallel-groupTriple-blindSupportive care

Summary

This study is a two-arm placebo controlled randomized clinical trial, to assess the effect of a 12-week EGCG intervention on physical frailty compared to placebo in pre-frail older cancer survivors.

Timeline

Start
2024-10-25
Primary completion
2030-01-01
Completion
2030-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Epigallocatechin gallate Small molecule 800 mg

Indications

No indication recorded.